# Evaluating New Formulation of Therapeutic HSV-2 Vaccine

> **NCT02515175** · PHASE2 · COMPLETED · sponsor: **Genocea Biosciences, Inc.** · enrollment: 131 (actual)

## Conditions studied

- Genital Herpes Simplex Type 2

## Interventions

- **BIOLOGICAL:** Matrix-M2
- **BIOLOGICAL:** GEN-003
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02515175
- **Lead sponsor:** Genocea Biosciences, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-11
- **Primary completion:** 2016-07
- **Final completion:** 2017-05-25
- **Target enrollment:** 131 (ACTUAL)
- **Last updated:** 2018-05-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02515175

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02515175, "Evaluating New Formulation of Therapeutic HSV-2 Vaccine". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02515175. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*